An open-label, single-center, study to determine the absorption, distribution, metabolism, and excretion (ADME) of LBH589 after a single oral administration of 20 mg (14C) LBH589 om advanced cancer patients.
Phase of Trial: Phase I
Latest Information Update: 30 Apr 2012
At a glance
- Drugs Panobinostat (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors Novartis
- 30 Apr 2012 Company Novartis Pharmaceuticals added to the associations field as reported by ClinicalTrials.gov.
- 30 Apr 2012 Actual patient number is 4 according to ClinicalTrials.gov.
- 30 Apr 2012 Actual end date (Jun 2008) added as reported by ClinicalTrials.gov.